Novartis to Pay $422.5 Million to End Trileptal Probes - BusinessWeek
Links shared publicly online about this topic.
- 835total visits
Novartis to Pay $422.5 Million to End Trileptal Probes - BusinessWeek
A U.S. unit of Novartis AG, the Swiss drugmaker, agreed to pay $422.5 million to resolve criminal and civil investigations into the marketing of its epilepsy drug Trileptal.
View full resource at businessweek.com
Tags: Seizure, Seizure Medication, Epilepsy, Drug, Trileptal, Novartis, Epilepsy Medication, Violence
Most Recently Shared on September 30, 2010 at 5:34 pm By:
Latest off-label settlement. Novartis to Pay $422.5 Million to End Trileptal Probes Bberg: http://bit.ly/d7vLPN h/t @pharmalot
Advertisement
